Scientific literature
The table below lists 29 publications that have reported genetic associations for Levodopa-induced dyskinesia in Parkinson's disease. You can sort the table according to a certain column by clicking on the column name. You can also download the data. If you think that we missed a publication, please help us to further improve this resource by contacting us.
| Reference | Title | Pubmed ID | Note |
|---|---|---|---|
| Bialecka et al. 2004 | Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. | 15355491 | Gene/variant curated |
| Cheshire al. 2014 | Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease. | 24008922 | Gene/variant curated |
| Contin et al. 2005 | Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. | 15747357 | No gene/variant curated |
| de Lau et al. 2011 | Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. | 22083803 | Gene/variant curated |
| Dos Santos et al. 2018 | The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease. | 30353564 | Gene/variant curated |
| Foltynie et al. 2009 | BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. | 18977816 | Gene/variant curated |
| Greenbaum et al. 2013 | Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study. | 23666822 | No gene/variant curated |
| Hao et al. 2014 | Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population. | 25034874 | Gene/variant curated |
| Healy et al. 2008 | Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. | 18539534 | Gene/variant curated |
| Ivanova et al. 2012 | NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. | 22832729 | No gene/variant curated |
| Kaiser et al. 2003 | L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. | 12796525 | Gene/variant curated |
| Kaplan et al. 2014 | Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease. | 24633632 | Gene/variant curated |
| König et al. | Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease | submitted | Meta-analysis results |
| Kusters et al. 2018 | Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease. | 29191473 | Gene/variant curated |
| Lee et al. 2011 | Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. | 20945430 | Gene/variant curated |
| Lesage et al. 2008 | Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease? | 18981379 | Gene/variant curated |
| Lin et al. 2007 | Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. | 17196621 | No gene/variant curated |
| Martín-Flores et al. 2019 | MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients. | 29992529 | Gene/variant curated |
| Molchadski et al. 2011 | The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. | 21108621 | No gene/variant curated |
| Oliveri et al. 1999 | Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. | 10534246 | Gene/variant curated |
| Paus et al. 2009 | Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. | 19353703 | No gene/variant curated |
| Purcaro et al. 2019 | DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease. | 30316985 | Gene/variant curated |
| Rieck et al. 2012 | DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. | 23171335 | Gene/variant curated |
| Rieck et al. 2015 | Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients? | 25872644 | Gene/variant curated |
| Rivera-Calimlim et al. 1984 | Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. | 6734032 | No gene/variant curated |
| Schumacher-Schuh et al. 2014 | Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. | 24126708 | Gene/variant curated |
| Strong et al. 2006 | Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. | 16435402 | Gene/variant curated |
| Torkaman-Boutorabi et al. 2012 | The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease. | 23093014 | No gene/variant curated |
| Watanabe et al. 2003 | Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. | 14673217 | No gene/variant curated |
| Yahalom et al. 2012 | Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. | 22703868 | No gene/variant curated |
| Zappia et al. 2005 | Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. | 15824260 | Gene/variant curated |